Current Research
Contents
All Peer Reviewed
There are two FDA-approved drugs for male-pattern hair loss and one for women, despite the fact that up to 80% of men and almost 50% of women experience significant hair loss throughout their lives.
But one chemical has stepped up to the task as millions of people across the world look for a means to slow down or stop baldness.
As stated in recent hair loss research from the University of California, Riverside, understanding transforming growth factor beta (TGF-) may be the key to curing baldness.
The study, which was published in the Biophysical Journal, identified TGF- as the moderator of the hair follicle growth cycle, dictating when hair follicle cells grow and when they die. TGF is one of many tiny proteins known as cytokines that help control other immune system cells and blood cells.
The research also explores regenerative medicine by looking at hair follicles, a source of stem cells. It offers a model to hasten wound healing. But this isn’t the only research out there.
Below, we invite you to check out the latest in peer-reviewed science on hair loss.
Current Hair Loss Research
-
Absence of oncomodulin increases susceptibility to noise-induced outer hair cell death and alters mitochondrial morphology
by Kaitlin E Murtha on November 7, 2024 at 11:00 am
Cochlear outer hair cells (OHCs) play a fundamental role in the hearing sensitivity and frequency selectivity of mammalian hearing and are especially […]
-
Exploring Mesenchymal Stem Cells versus Minoxidil for Androgenic Alopecia Treatment: A detailed Animal-Based Histological and Morphometric Study
by Sherif A Kamar on November 11, 2024 at 11:00 am
CONCLUSION: HUCB-MSC therapy demonstrated superior efficacy over minoxidil with no observed side effects, indicating its potential as a promising […]
-
Contributions of mirror-image hair cell orientation to mouse otolith organ and zebrafish neuromast function
by Kazuya Ono on November 12, 2024 at 11:00 am
Otolith organs in the inner ear and neuromasts in the fish lateral-line harbor two populations of hair cells oriented to detect stimuli in opposing […]
-
Commentary on Low-Level Laser and Led Therapy in Alopecia: A Systematic Review and Meta-Analysis
by Dawn Queen on November 12, 2024 at 11:00 am
No abstract
-
Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN-FRT evaluation
by Phyllis Spuls on November 12, 2024 at 11:00 am
No abstract
Interesting to Note
KeraMedix, a brand-new intriguing firm focused on hair development, has once more arisen from Korea.
Researchers from Kyung Hee and Konkuk Universities in South Korea published their paper, “Keratin-mediated hair development and its underlying biological mechanism,” on November 19, 2022 in the Communications Biology magazine of Nature Portfolio.
According to this peer-reviewed study, an exclusive type of injectable keratin can promote hair development in an animal model. The study is highly detailed and has a ton of information for anyone who want to look over its supporting documentation. However, we’re quite aware that the majority of this readership is only concerned with the financial benefits of such an injectable technology.
KeraMedix Biotech Company
According to its website, KeraMedix is a bio-venture firm with headquarters in Seoul, South Korea, and was established in 2017.
The company’s CEO is Dr. Song-wook Han.
Four prospective medicines are now visible in KeraMedix’s pipeline (shown below): first- and second-generation injectables for hair growth, an injectable for diabetic ulcers, and an injectable for skin rejuvenation.
It’s fascinating to note that a sophisticated technique actually uses human hair to create the keratin protein that is employed in these injectable medicines.